drugset / Trial / NCT00019734

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00019734

RandomizedTreatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy with and without interleukin-2 in treating patients who have metastatic melanoma that has not responded to previous treatment.

Timeline

Start
1999-07
Primary completion
Completion
2003-05

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic Subcutaneous
Subject fowlpox virus vaccine vector Vaccine Intramuscular
Subject vaccinia-tyrosinase vaccine Vaccine Intramuscular

Indications